AU4068599A - Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction - Google Patents

Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction

Info

Publication number: AU4068599A
Authority: AU; Australia
Prior art keywords: phentolamine; treatment; combination; sexual dysfunction; phosphodiesterase inhibitors
Prior art date: 1998-05-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU40685/99A

Inventor

Thomas Mark Estok

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Merck Sharp and Dohme LLC

Original Assignee

Schering Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-05-20

Filing date

1999-05-17

Publication date

1999-12-06

1999-05-17 Application filed by Schering Corp filed Critical Schering Corp

1999-12-06 Publication of AU4068599A publication Critical patent/AU4068599A/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AU40685/99A 1998-05-20 1999-05-17 Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction Abandoned AU4068599A (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US8164098A	1998-05-20	1998-05-20
US09081640		1998-05-20
US8297798A	1998-05-21	1998-05-21
US09082977		1998-05-21
US10651798A	1998-06-29	1998-06-29
US09106517		1998-06-29
PCT/US1999/007046 WO1999059584A1 (en)	1998-05-20	1999-05-17	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction

Publications (1)

Publication Number	Publication Date
AU4068599A true AU4068599A (en)	1999-12-06

Family

ID=27374039

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU40685/99A Abandoned AU4068599A (en)	1998-05-20	1999-05-17	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction

Country Status (3)

Country	Link
AU (1)	AU4068599A (en)
PE (1)	PE20000547A1 (en)
WO (1)	WO1999059584A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU769946B2 (en) *	1999-04-30	2004-02-12	Icos Corporation	Unit dosage form

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1161255A4 (en) *	1999-03-08	2002-07-17	Merck & Co Inc	METHODS AND COMPOSITIONS FOR THE TREATMENT OF DYSERECTION
US6943166B1 (en)	1999-04-30	2005-09-13	Lilly Icos Llc.	Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
TWI265925B (en)	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
BRPI0003386B8 (en)	2000-08-08	2021-05-25	Cristalia Produtos Quim Farmaceuticos Ltda	homo- or heterodimeric prodrugs useful in treating diseases or disorders mediated by phosphodiesterases; pharmaceutical compositions containing the prodrug or its pharmaceutical acceptable salts; process of obtaining these prodrugs
UA78974C2 (en)	2001-10-20	2007-05-10	Boehringer Ingelheim Pharma	Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en)	2001-10-20	2020-06-09	Sprout Pharmaceuticals, Inc.	Treating sexual desire disorders with flibanserin
ES2646326T3 (en)	2005-08-03	2017-12-13	Sprout Pharmaceuticals, Inc.	Use of flibanserin in the treatment of obesity
CA2626134C (en)	2005-10-29	2013-12-24	Boehringer Ingelheim International Gmbh	Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
ATE456369T1 (en)	2006-06-30	2010-02-15	Boehringer Ingelheim Int	FLIBANSERIN FOR THE TREATMENT OF URINARY INCONTINENCE AND ASSOCIATED DISEASES
AU2007286288A1 (en)	2006-08-14	2008-02-21	Boehringer Ingelheim International Gmbh	Formulations of flibanserin and method for manufacturing the same
BRPI0716436B8 (en)	2006-08-25	2021-05-25	Boehringer Ingelheim Int	controlled release system and method for manufacturing it
CL2008002693A1 (en)	2007-09-12	2009-10-16	Boehringer Ingelheim Int	Use of flibanserin for the treatment of selected vasomotor symptoms of hot flashes, night sweats, mood swings, and irritability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69423533T2 (en) *	1993-02-10	2000-08-24	B.M.R.A. Corp. B.V., Rotterdam	Preparations for the treatment of impotence, which contain an alpha-1 inhibitor and an alpha-2 inhibitor
GB9301192D0 (en) *	1993-06-09	1993-06-09	Trott Francis W	Flower shaped mechanised table
US5731339A (en) *	1995-04-28	1998-03-24	Zonagen, Inc.	Methods and formulations for modulating the human sexual response
GB9514464D0 (en) *	1995-07-14	1995-09-13	Glaxo Lab Sa	Medicaments

1999
- 1999-05-17 AU AU40685/99A patent/AU4068599A/en not_active Abandoned
- 1999-05-17 WO PCT/US1999/007046 patent/WO1999059584A1/en not_active Ceased
- 1999-05-18 PE PE1999000419A patent/PE20000547A1/en not_active Application Discontinuation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU769946B2 (en) *	1999-04-30	2004-02-12	Icos Corporation	Unit dosage form
AU769946C (en) *	1999-04-30	2005-01-13	Icos Corporation	Unit dosage form

Also Published As

Publication number	Publication date
PE20000547A1 (en)	2000-07-15
WO1999059584A1 (en)	1999-11-25

Publication	Publication Date	Title
IL138907A0 (en)	2001-11-25	Pyrazolopyrimidinone cgmp pde5 inhibitors for the treatment of sexual dysfunction
EP1027054A4 (en)	2002-11-04	Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction
AU5785699A (en)	2000-04-03	Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents
AU4583899A (en)	2000-01-10	Nasal administration of sildenafil for the treatment of erectile dysfunction
EP1143987A4 (en)	2004-09-22	Natural composition and method for the treatment of sexual dysfunction
GB9824436D0 (en)	1999-01-06	Methods of treatment
PL345338A1 (en)	2001-12-17	Method for the treatment of insomnia
IL155589A0 (en)	2003-11-23	Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
AP2000001796A0 (en)	2000-06-30	The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
AP9801414A0 (en)	1998-12-31	Combination effective for the treatment of impotence
AU4068599A (en)	1999-12-06	Combination of phentolamine and cyclic gmp phosphodiesterase inhibitors for the treatment of sexual dysfunction
AU2001250821A1 (en)	2001-09-24	Methods and compositions for the treatment and prevention of erectile dysfunction
HUP0200912A3 (en)	2003-07-28	Compositions comprising phosphodiesterase inhibitors for the treatment of sexual disfunction
AU3894600A (en)	2000-10-09	Method of treating sexual dysfunction
AU6562100A (en)	2001-02-05	Method for the anticorrosive treatment or post-treatment of metal surfaces
PL361733A1 (en)	2004-10-04	Sulfamidothienopyrimidines and the use of the same as phosphodiesterase v inhibitors
AU4676099A (en)	2000-01-05	Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
AU5509099A (en)	2000-02-28	Pyridinones for the treatment of sexual dysfunction
AU7652400A (en)	2001-04-17	Novel combination for the treatment of sexual dysfunction
AU8906201A (en)	2002-03-26	Methods and compositions for the treatment and prevention of sexual dysfunction
AU1646201A (en)	2001-05-10	Pharmaceutical agent for the treatment of cachexia and/or cardiogenic shock
IL137439A0 (en)	2001-07-24	Method for the determination of prosthetic infections
AU2566201A (en)	2001-07-09	Compounds and methods for the treatment of pain
AU2002342715A1 (en)	2002-11-25	Novel methods for the treatment and prevention of pain using stress-activated protein kinase inhibitors
IL150208A0 (en)	2002-12-01	Compound and method for the treatment of pain

Legal Events

Date	Code	Title	Description
2001-02-08	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase